Tresiba Cost in Delaware 2026: What You'll Actually Pay

What Is the Actual Tresiba List Price in Delaware for 2026?

Novo Nordisk sets the wholesale acquisition cost for Tresiba (insulin degludec) at approximately $510 per month for a standard supply of 5 FlexTouch pens (300 units each, 100 units/mL). Almost nobody pays that figure. After pharmacy benefit negotiations, copay cards, and discount programs, the real out-of-pocket number for most Delaware residents sits far below the sticker price.

The gap between list and actual cost exists because pharmacy benefit managers extract rebates from manufacturers before claims are processed. Those rebates are not passed directly to patients at the point of sale unless the patient is enrolled in a high-deductible plan or is uninsured. Insulin pricing opacity has been studied extensively; a 2021 JAMA Internal Medicine analysis found that list prices for insulin analogs increased 54% between 2014 and 2019, while net prices after rebates were substantially lower but not transparent to patients. [1]

The FDA approved Tresiba in September 2015 for glycemic control in adults and, following a label expansion, for pediatric patients aged 1 year and older. [2] Degludec's ultra-long half-life of approximately 25 hours produces a flat, stable pharmacokinetic profile that differentiates it from insulin glargine U-300 and insulin glargine U-100. [3]

Tresiba is available in two concentrations: 100 units/mL (U-100) and 200 units/mL (U-200). The U-200 pen delivers up to 160 units per injection and may reduce the number of pen changes for high-dose patients, but the per-unit cost is equivalent. [2]

How Much Do Delaware Residents Actually Pay at the Pharmacy?

With a GoodRx or similar discount card applied at a Delaware retail pharmacy, the average cash price for a 30-day supply of Tresiba 100 units/mL FlexTouch (5 pens) runs approximately $35 in 2026. That is a reduction of more than 93% from list price. Prices vary by pharmacy chain; large chains including CVS, Walgreens, and Rite Aid participate in discount pricing networks, and independent pharmacies in Wilmington, Dover, and Newark often match or beat chain prices when the discount card is presented.

GoodRx-type cards work by routing the claim through a pharmacy benefit administrator at a pre-negotiated rate. They are not insurance. The patient pays cash and cannot simultaneously apply a manufacturer copay card or insurance benefit on the same fill. Choosing between discount card and insurance requires a quick comparison at your specific pharmacy.

A 2022 Health Affairs analysis confirmed that discount cards substantially reduce insulin out-of-pocket costs for uninsured patients but may generate claims that count against deductibles differently across plan types. [4] Delaware residents on high-deductible health plans should check whether running the claim through insurance first during early-year deductible accumulation is cheaper than the cash-pay route.

Pharmacists at any Delaware licensed pharmacy can run a benefits check in real time. Ask specifically for the "best price" comparison across your insurance, GoodRx, and the Novo Nordisk savings card simultaneously before the claim is submitted.

Does Delaware Medicaid Cover Tresiba?

Delaware Medicaid (Diamond State Health Plan and Diamond State Health Plan Plus, administered through managed care organizations) covers Tresiba for both type 1 and type 2 diabetes with prior authorization (PA). [5] The PA requirement typically asks the prescriber to document that the patient has tried at least one preferred long-acting insulin (usually insulin glargine U-100, listed on the preferred drug list without restriction) and either experienced inadequate glycemic control or a specific clinical reason why degludec is more appropriate.

Prior authorization is not a denial. It is a documentation step that your prescriber completes. Most Delaware endocrinologists and primary care physicians are familiar with the PA process. Turnaround time under Delaware Medicaid managed care organizations is generally 72 hours for standard reviews and 24 hours for urgent requests under federal Medicaid managed care regulations at 42 CFR 438.210. [6]

If the PA is approved, Medicaid members typically pay $0 to $3 per fill depending on their specific managed care plan and income tier. Delaware expanded Medicaid under the ACA, so adults with incomes up to 138% of the federal poverty level qualify. [5]

Patients who are denied can request a formulary exception or a state fair hearing. The Delaware Division of Medicaid and Medical Assistance (DMMA) processes fair hearing requests within 90 days, and coverage may be maintained during the appeal period if the patient was previously receiving the drug. [6]

Which Private Insurance Plans Cover Tresiba in Delaware?

Most commercial plans sold in Delaware cover Tresiba, though tier placement varies considerably. The state's largest commercial insurers include Highmark Blue Cross Blue Shield of Delaware, Aetna, UnitedHealthcare, and Cigna. Coverage tiers for insulin degludec range from Tier 2 (preferred brand, lower copay) to Tier 3 (non-preferred brand, higher copay) depending on the plan year and formulary.

The practical decision tree for Delaware patients with commercial insurance:

1. Call the number on the back of your insurance card and ask for the "formulary tier" for insulin degludec (NDC 00169-4060-15 for U-100 FlexTouch, 5-pack).
2. Ask whether a prior authorization or step therapy requirement applies.
3. If Tresiba is Tier 3, ask whether an exception or formulary override is available with a letter of medical necessity from your prescriber.
4. Compare the resulting copay against the Novo Nordisk savings card cap of $99 per month for eligible commercially insured patients.

Under the Inflation Reduction Act, Medicare Part D insulin cost-sharing is capped at $35 per month per covered insulin as of 2023. [7] Tresiba is covered under multiple Part D formularies available to Delaware Medicare beneficiaries. Patients should use the Medicare Plan Finder at medicare.gov to confirm formulary inclusion for their specific plan before open enrollment closes each December 7.

Delaware employers with self-funded plans (common among large employers like ChristianaCare and Nemours) set their own formularies. These plans are governed by ERISA, not state insurance mandates, so benefits vary widely. Contact your HR benefits administrator or pharmacy benefit manager directly.

Are There Tresiba Discount Programs for Delaware Patients?

Several programs reduce or eliminate Tresiba costs for Delaware residents who qualify.

Novo Nordisk Patient Assistance Program (NovoCare). Patients without insurance or whose insurance does not cover Tresiba may qualify for free medication through NovoCare if household income falls at or below 400% of the federal poverty level. Applications are submitted through the prescriber's office. [8]

Novo Nordisk Savings Card. Commercially insured patients (not Medicare or Medicaid) can use the Novo Nordisk savings card to cap monthly cost at $99 or less per prescription. This card cannot be used with federal or state government insurance programs. Income limits do not apply for the savings card. [8]

GoodRx and Cost-Plus Drugs. As noted above, discount aggregators bring cash-pay prices to approximately $35 per month at participating Delaware pharmacies. Mark Cuban's Cost Plus Drugs platform listed insulin degludec at reduced pricing in 2024 and may offer further reductions in 2026, though formulary inclusion should be confirmed at the time of purchase.

Delaware's Prescription Assistance Programs. The Delaware ASSIST program and the Delaware Prescription Drug Program (PDP) help low-income state residents access medications. Eligibility is separate from Medicaid. Residents aged 65 and older with incomes up to 200% of the federal poverty level may qualify for additional cost-sharing reductions on outpatient prescriptions. [9]

The American Diabetes Association's "Insulin Help" resource consolidates manufacturer and state programs in a single directory and is updated quarterly. [10] The ADA's 2024 Standards of Care state directly: "Clinicians should be aware of the cost of insulin and work with patients to find affordable options." [10]

Is Compounded Insulin Degludec Legal in Delaware?

Compounded insulin degludec is available in Delaware through 503A compounding pharmacies, and its legal status is nuanced but currently permissible under specific conditions. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner. [11]

FDA has not placed insulin degludec on the list of drug products that may not be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. This means a 503A pharmacy with a licensed pharmacist in Delaware may compound insulin degludec for a specific patient with a valid prescription, provided the compound is not a copy of a commercially available product without clinical differentiation. [11]

The practical cost is dramatic. Some 503A compounding pharmacies offer compounded insulin degludec at effectively $0 to the patient when billed through certain telehealth platforms that include pharmacy costs in a subscription fee. Others charge a direct cash price substantially below the commercial Tresiba list price. Quality and potency consistency in compounded insulin products vary, and the FDA has expressed concern about compounded hormone and peptide products broadly. [11]

A 2023 JAMA study evaluating compounded semaglutide raised questions about concentration accuracy in compounded GLP-1 products; similar analytical work on compounded basal insulins is limited in the peer-reviewed literature, but the concentration risk principle applies. [12] Patients and prescribers should verify that the 503A pharmacy holds a current Delaware Board of Pharmacy license and that the compound has been tested for sterility and potency by the compounding facility.

Delaware Board of Pharmacy licensing information is publicly searchable at the Division of Professional Regulation website. Never fill a compounded insulin prescription from an unlicensed or out-of-state pharmacy not registered to dispense to Delaware residents.

Can I Get a Tresiba Prescription Through Telehealth in Delaware?

Telehealth prescribing of Tresiba is legal in Delaware. A licensed physician, advanced practice registered nurse (APRN), or physician assistant with Delaware prescribing authority may prescribe insulin degludec via a synchronous video visit without requiring an in-person examination, provided the clinical standard of care is met. [13]

Delaware adopted permanent telehealth flexibilities in 2023 under House Bill 110, which removed the requirement that a prior in-person relationship exist before a controlled or non-controlled prescription may be issued via telehealth for conditions like diabetes. Insulin is not a controlled substance, so it faces fewer prescribing restrictions than, for example, GLP-1 agonists in certain states. [13]

For a telehealth visit to result in a valid Tresiba prescription in Delaware, the clinician must:

• Conduct a synchronous audio-video interaction (asynchronous "store-and-forward" is insufficient for prescribing in most cases).
• Document a clinical evaluation sufficient to establish a diagnosis of type 1 or type 2 diabetes.
• Review recent HbA1c, fasting glucose, or continuous glucose monitor data.
• Counsel the patient on injection technique, hypoglycemia recognition, and dose titration.

HealthRX clinicians prescribe Tresiba to Delaware residents through synchronous telehealth visits. A prescription can be sent to any Delaware-licensed retail or compounding pharmacy the patient designates.

What Does the Clinical Evidence Say About Tresiba's Effectiveness?

Tresiba's cardiovascular safety was confirmed in the DEVOTE trial, a randomized, double-blind, treat-to-target study that enrolled 7,637 patients with type 2 diabetes at high cardiovascular risk. [14] DEVOTE compared insulin degludec to insulin glargine U-100 and found non-inferiority for the primary endpoint of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). The hazard ratio was 0.91 (95% CI 0.78 to 1.06), confirming non-inferiority (P<0.001). [14]

A secondary finding from DEVOTE was a 40% lower rate of severe hypoglycemia with degludec versus glargine U-100 (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [14] Severe hypoglycemia in type 2 diabetes increases emergency department visits and carries its own cardiovascular risk, so this finding has direct clinical and cost implications. Fewer hypoglycemia events may mean fewer missed workdays, fewer 911 calls, and lower downstream healthcare utilization for Delaware patients.

The BEGIN trial program (multiple phase 3 studies across type 1 and type 2 diabetes) established that degludec achieves similar HbA1c reductions to glargine U-100 with comparable or lower fasting plasma glucose variability. [15] In BEGIN BASAL-BOLUS TYPE 1 (N=629), degludec reduced overall hypoglycemia rates by 11% and nocturnal rates by 25% versus glargine U-100 after 52 weeks. [15]

The 2024 American Diabetes Association Standards of Medical Care in Diabetes place ultra-long-acting insulins including degludec as an appropriate basal insulin option across both type 1 and type 2 diabetes, with preference for degludec or glargine U-300 in patients with recurrent nocturnal hypoglycemia. [10]

The Endocrine Society's clinical practice guideline on insulin therapy notes that "insulin degludec's prolonged duration of action of more than 42 hours allows for greater flexibility in injection timing without clinically meaningful changes in glycemic control or safety." [16] This characteristic is particularly relevant for patients with variable schedules, shift workers, and those managing insulin around Delaware's agricultural or service-industry work patterns.

How Does Degludec Compare to Other Basal Insulins on Cost in Delaware?

Insulin glargine U-100 (Lantus, Basaglar) is the most common competitor. Basaglar, a biosimilar to Lantus, carries a Delaware cash-pay price of approximately $20 to $25 per month with discount cards in 2026, making it cheaper than Tresiba's cash-pay equivalent. Toujeo (glargine U-300) runs approximately $30 to $40 per month cash-pay. [17]

The cost difference between degludec and glargine biosimilars is real but may be offset by clinical outcomes. In patients with recurrent nocturnal hypoglycemia, the SWITCH 2 trial (N=721, type 2 diabetes) found a 35% reduction in symptomatic nocturnal hypoglycemic events when patients crossed over from glargine U-100 to degludec. [18] Fewer hypoglycemia events reduce downstream costs including emergency visits, ambulance transport, and productivity loss, though a formal cost-effectiveness analysis for Delaware specifically has not been published.

Insulin glargine biosimilars approved by the FDA through the 351(k) pathway include Basaglar (approved 2015) and Semglee (approved 2021, the first interchangeable insulin biosimilar). [19] No interchangeable biosimilar for insulin degludec had received FDA approval as of early 2025, meaning pharmacists in Delaware cannot automatically substitute a biosimilar at dispensing without a new prescription.

For Delaware patients primarily driven by cost, the decision pathway is clear: if Basaglar or Semglee controls glycemia with tolerable hypoglycemia rates, the lower cash price is a practical advantage. If nocturnal hypoglycemia, injection timing flexibility, or high daily doses are concerns, degludec's clinical profile may justify the modest price premium.

Dose Titration and Practical Starting Points for Delaware Patients

Standard starting doses for insulin degludec in insulin-naive type 2 diabetes patients are 10 units subcutaneously once daily, or 0.1 to 0.2 units/kg/day, per Novo Nordisk prescribing information. [2] Titration proceeds by 2 units every 3 days based on fasting glucose targets, with a target fasting glucose of 80 to 130 mg/dL per ADA 2024 guidelines. [10]

Injection site rotation across the abdomen, thigh, or upper arm reduces lipohypertrophy risk. Because degludec's pharmacodynamic profile is flat over 42 hours, injection timing can shift up to 8 hours from day to day without clinically meaningful glycemic impact, a property confirmed in a crossover pharmacokinetic study published in Diabetes Care. [20]

Storage before opening: Tresiba pens may be stored at room temperature (below 86 degrees Fahrenheit) or in a refrigerator (36 to 46 degrees Fahrenheit). After first use, pens should not be refrigerated and should be discarded after 56 days. [2] Delaware's summer humidity does not degrade the pen if kept out of direct sunlight.

Patients switching from once-daily glargine U-100 or glargine U-300 to degludec convert on a unit-to-unit basis. Patients switching from twice-daily NPH insulin should reduce the total daily dose by 20% when initiating degludec to reduce hypoglycemia risk during transition. [2]